In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 14, 2025), Rosalind Advisors, Inc. reported 29 stock positions worth $206.6 million . Its top holding was Delcath Systems (DCTH) at 16.0% of the portfolio, followed by Fennec Pharmaceuticals (FENC, 8.2% ) and Cytokinetics (CYTK, 6.4% ). Compared with Q1 2025, it opened 4 new positions, sold out of 6, added to 7 and reduced 9. The biggest buy was a new position in Cytokinetics (CYTK) and the biggest sale an exit from Abeona Therapeutics (ABEO).
Location TORONTO, A6
CIK 0001622627
Portfolio Value $206.6M (Q2 2025) Holdings 29 stocks · $206.6M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q1 2025 DCTH Delcath Systems Inc. 3,300,389 $33.0M Add +13.8% FENC Fennec Pharmaceuticals Inc. 2,045,644 $17.0M Add +14.7% CYTK Cytokinetics Inc. 400,000 $13.2M New OCUL Ocular Therapeutix Inc. 1,218,700 $11.3M No change IDYA Ideaya Biosciences Inc. 511,132 $10.7M Reduce -27.0% XERS Xeris Biopharma Holdings Inc. 2,155,594 $10.1M Reduce -13.6% VRDN Viridian Therapeutics Inc. 700,000 $9.8M Add +17.6% VRNA Verona Pharma Ltd. 100,000 $9.5M No change VSTM Verastem Inc. 2,043,563 $8.5M Reduce -22.7% REPL Replimune Group Inc. 900,000 $8.4M Add +5.9% MDWD Mediwound Ltd. 407,061 $7.9M Reduce -19.7% MYO Myomo Inc. 3,595,788 $7.8M Add +33.0% RZLT Rezolute Inc. 1,741,211 $7.8M New URGN Urogen Pharma Ltd. 542,366 $7.4M Reduce -42.9% HELP Cybin Inc. 810,918 $6.8M No change SVRA Savara Inc. 2,654,944 $6.1M No change NSPR Inspiremd Inc. 2,289,099 $5.2M Add +0.6% CGON CG Oncology Inc. 192,974 $5.0M New PROF Profound Medical Corp. 692,185 $4.1M No change PHVS Pharvaris NV 223,627 $3.9M No change PYPD Polypid Ltd. 975,462 $3.4M Reduce -4.2% MIND MEDICINE MINDMED INC 420,000 $2.7M No change KALV Kalvista Pharmaceuticals Inc. 157,725 $1.8M Reduce -48.1% TRVI Trevi Therapeutics Inc. 300,000 $1.6M Reduce -51.0% CMPS Compass Pathways PLC 482,651 $1.4M Reduce -41.4% TLPH Talphera Inc. 2,003,939 $922K No change BFRI Biofrontera Inc. 976,448 $695K Add +51.5% KURA Kura Oncology Inc. 100,000 $577K No change OVID Ovid Therapeutics Inc. 500,000 $165K New
Options reported separately and not counted above: INMUNE BIO INC puts ($1.8M), UROGEN PHARMA LTD calls ($600K), SPDR SERIES TRUST puts ($534K), REPLIMUNE GROUP INC calls ($516K), STATE STR SPDR S&P 500 ETF T puts ($433K), ATYR PHARMA INC puts ($271K), IDEAYA BIOSCIENCES INC calls ($68K), CRINETICS PHARMACEUTICALS IN calls ($58K).
Portfolio Sells Q1 2025 → Q2 2025 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2025 % Of Portfolio Change To Portfolio ▲ ABEO Abeona Therapeutics Inc. Sold out 0.00% −4.19 VSTM Verastem Inc. Reduce -22.7% 4.10% −3.67 NUVB Nuvation Bio Inc. Sold out 0.00% −2.10 XERS Xeris Biopharma Holdings Inc. Reduce -13.6% 4.87% −1.81 URGN Urogen Pharma Ltd. Reduce -42.9% 3.60% −1.52 OPTINOSE INC Sold out 0.00% −1.14 TRVI Trevi Therapeutics Inc. Reduce -51.0% 0.79% −1.08 KALV Kalvista Pharmaceuticals Inc. Reduce -48.1% 0.86% −0.85 COGT Cogent Biosciences Inc. Sold out 0.00% −0.72 CMPS Compass Pathways PLC Reduce -41.4% 0.65% −0.49 IDYA Ideaya Biosciences Inc. Reduce -27.0% 5.20% −0.39 KPRX Kiora Pharmaceuticals Inc. Sold out 0.00% −0.37 ACOG Alpha Cognition Inc. Sold out 0.00% −0.26 MDWD Mediwound Ltd. Reduce -19.7% 3.82% −0.02 PYPD Polypid Ltd. Reduce -4.2% 1.67% +0.32
Portfolio Buys Q1 2025 → Q2 2025 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2025 % Of Portfolio Change To Portfolio ▼ CYTK Cytokinetics Inc. New 6.40% +6.40 RZLT Rezolute Inc. New 3.76% +3.76 FENC Fennec Pharmaceuticals Inc. Add +14.7% 8.22% +2.93 CGON CG Oncology Inc. New 2.43% +2.43 DCTH Delcath Systems Inc. Add +13.8% 15.97% +1.84 VRDN Viridian Therapeutics Inc. Add +17.6% 4.74% +0.83 BFRI Biofrontera Inc. Add +51.5% 0.34% +0.09 OVID Ovid Therapeutics Inc. New 0.08% +0.08 REPL Replimune Group Inc. Add +5.9% 4.05% +0.01 NSPR Inspiremd Inc. Add +0.6% 2.51% −0.47 MYO Myomo Inc. Add +33.0% 3.76% −2.58
Options Activity Q1 2025 → Q2 2025 Security Type Change vs Q1 2025 Underlying Shares Value ▼ INMUNE BIO INC put New 1,033,200 $1.8M UROGEN PHARMA LTD call New 100,000 $600K SPDR SERIES TRUST put New 550,000 $534K REPLIMUNE GROUP INC call New 231,800 $516K STATE STR SPDR S&P 500 ETF T put New 250,000 $433K INVESCO QQQ TR put Sold out 50,000 $374Kbefore exit ATYR PHARMA INC put New 223,000 $271K IDEAYA BIOSCIENCES INC call New 20,000 $68K CRINETICS PHARMACEUTICALS IN call New 52,700 $58K LEXICON PHARMACEUTICALS INC call Sold out 1,278,900 $30Kbefore exit CANDEL THERAPEUTICS INC put Sold out 15,800 $4Kbefore exit
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 29 $266.2M DCTH, FENC, XERS, SVRA, VSTM Q1 2026 32 $244.1M DCTH, XERS, FENC, SVRA, PCVX Q4 2025 29 $274.5M DCTH, SVRA, FENC, XERS, VRDN Q3 2025 29 $283.0M DCTH, CYTK, FENC, VSTM, RZLT Q2 2025 29 $206.6M DCTH, FENC, CYTK, OCUL, IDYA Q1 2025 31 $205.2M DCTH, VSTM, XERS, MYO, IDYA Q4 2024 Amended 28 $185.7M DCTH, MYO, MDWD, CMRX, XERS Q3 2024 29 $150.7M DCTH, MYO, CRMD, ABEO, MDWD Q2 2024 35 $126.5M DCTH, MYO, MDWD, OPTINOSE INC, ABEO Q1 2024 31 $106.9M MYO, LYRA, MDWD, OPTINOSE INC, XERS